Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exelixis, Inc. (EXEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed oncology-focused biopharmaceutical company, Exelixis uses these filings to report material events, financial results, capital allocation decisions and changes in senior leadership.
Form 8-K filings for EXEL include items such as quarterly financial results and corporate updates, stock repurchase program authorizations and executive appointments or departures. For example, Exelixis has filed 8-Ks describing the authorization of a stock repurchase program for up to a specified amount of common stock before a stated date, as well as the appointment of an Executive Vice President, Research and Development and the planned transition of its General Counsel role. These filings complement the company’s earnings press releases by providing structured information on results of operations and significant corporate actions.
Investors and analysts can use Exelixis’ SEC filings to track how the company reports revenue from its cabozantinib franchise, outlines research and development and selling, general and administrative expenses, and communicates guidance ranges for future periods. While detailed financial statements and management discussion are found in periodic reports such as Forms 10-K and 10-Q, current reports on Form 8-K highlight timely developments that may affect the company’s outlook or governance.
On Stock Titan, EXEL filings are accompanied by AI-powered summaries designed to clarify the key points in complex documents. These summaries help readers quickly understand the implications of new filings, from capital return plans to leadership changes, while links to the full text allow for deeper review. The filings page also serves as a starting point for researching topics such as repurchase authorizations, executive transitions and other events that Exelixis has deemed material enough to disclose under SEC rules.
EXELIXIS, INC. director Julie Smith reported combined option exercises and stock sales. On February 17–18, 2026, she exercised options covering a total of 106,539 shares of common stock at exercise prices of $18.19, $19.39 and $21.69 per share.
Over the same two days she sold 106,539 shares of Exelixis common stock in open-market transactions at prices including $43.33, $44.30 and $44.50 per share, resulting in a net sale position. After these trades she directly owned 20,590 shares of common stock, and a footnote states she also holds 9,812 restricted stock units that will settle into common shares upon vesting.
EXEL affiliate filing a Form 144 to report proposed resale of common stock derived from performance-share awards. The notice lists multiple tranches of performance shares dated 08/03/2022 (6,385), 02/15/2022 (8,986), 02/03/2021 (11,543) and 11/15/2021 (2,959), and identifies Morgan Stanley Smith Barney LLC as the broker-dealer. Timing and cash‑flow treatment are as reported in the notice.
Exelixis, Inc. executive Christopher J. Senner, EVP and CFO, reported net stock sales. On February 13 and 17, 2026, he executed open‑market sales of Exelixis common stock totaling 64,895 shares at prices around $43–$44 per share.
On February 15, 2026, an additional 35,870 shares were disposed of to cover taxes due on previously granted performance‑based restricted stock units, rather than sold for cash. After these transactions, he directly owned 976,092 shares, which include 427,690 shares underlying RSUs and performance stock units, and indirectly held 2,723 shares through the Exelixis 401(k) plan.
Exelixis, Inc. executive Patrick J. Haley, EVP Commercial, reported significant insider share activity. On February 17, 2026, he executed two open-market sales of Exelixis common stock totaling 67,814 shares, with 3,036 shares sold at $43.84 per share and 64,778 shares sold at $43.50 per share.
On February 15, 2026, 31,483 shares were disposed of to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022, after performance criteria were certified on January 16, 2025. Following these transactions, Haley holds 381,908 shares, a figure that includes restricted stock units and performance stock units granted on March 31, 2025, each representing or economically equivalent to one share of common stock.
EXELIXIS, INC. President and CEO Michael Morrissey reported multiple equity transactions in company common stock. He exercised an option for 494,700 shares on February 13, 2026 at a stated exercise price of $21.31 per share, increasing his direct holdings.
To cover the option exercise price and related taxes, 369,606 shares were withheld at $43.92 per share, and a further 120,390 shares were withheld on February 15, 2026 to satisfy tax liabilities after performance-based restricted stock units vested. Morrissey also made bona fide gifts totaling 501,472 shares over February 17–18, 2026, transferring shares to the Morrissey Family Trust, which holds shares as trustees.
A footnote states that 1,454,115 shares of common stock will be issued upon vesting of previously granted RSUs and performance stock units, each representing the right to receive one share of common stock.
Exelixis director Sue Gail Eckhardt reported an open-market sale of 3,856 shares of common stock on February 13, 2026 at a weighted average price of $43.79 per share. The transaction was executed under a prearranged Rule 10b5-1 trading plan adopted on November 11, 2025. After this sale, she beneficially owns 17,524 shares, including shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported two tax-related share dispositions. On February 15, 2026, a total of 26,485 and 12,720 shares of common stock were withheld at $43.92 per share to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022 and restricted stock units granted on January 5, 2023. These are tax-withholding dispositions, not open-market sales. After these transactions, Aftab directly holds 706,617 shares of common stock, which include 414,043 shares underlying restricted stock units and performance stock units granted on March 31, 2025. In addition, there are 5,835 shares held indirectly through the Exelixis 401(k) Plan as of February 13, 2026.
Exelixis, Inc. director Bob Oliver reported mixed activity in company stock. On February 13, 2026, he sold 9,088 shares of common stock in an open-market transaction at $43.61 per share and separately sold 21,162 shares at a weighted average price of $43.90 per share, with individual trades between $43.90 and $43.96 as noted in a footnote.
On the same date, he exercised an option for 9,088 shares of common stock, recorded as both a derivative exercise and an acquisition of common shares at an exercise price of $19.28 per share. A footnote states this option originally covered 36,353 shares and became fully exercisable on May 31, 2023. Another footnote notes 18,900 restricted stock units that will convert into common shares upon vesting.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti reported insider transactions in company common stock. She sold 18,669 shares in an open-market sale at an average price of $44.01 per share under a pre-arranged Rule 10b5-1 trading plan. Separately, 5,430 shares were withheld by the company to cover taxes due on the vesting of performance-based restricted stock units. After these transactions, she continued to hold a substantial direct equity position, along with additional restricted stock units, performance stock units expected to deliver 95,956 shares upon vesting, and 5,527 shares held indirectly through the company’s 401(k) plan.
Insider sale notice: A reporting person submitted a Form 144 indicating a proposed sale of 64,117 shares on 02/18/2026. The filing also reports prior sales of 42,422 shares on 02/17/2026 for $1,880,439.99.